Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC)

McGahan L
Record ID 32018000340
Authors' results and conclusions: Overall, adding atezolizumab to nab-paclitaxel as first-line therapy for advanced triple negative breast cancer (TNBC) prolongs progression-free survival (PFS) and reduces the risk of progression or death. The PFS benefit of atezolizumab combination therapy over chemotherapy alone was also consistent in the programmed death ligand 1 (PD-L1)-positive subgroup. These results are consistent with previous reports suggesting first-line atezolizumab, PD-L1 expression ≥1, and >10% tumour-infiltrating IC are independently associated with increased objective response rate (ORR) and PFS.
Authors' recomendations: Mature overall survival (OS) data and quality of life measures are needed to ensure patients achieve a clinically relevant benefit over time despite manageable toxicity. Further studies are needed to identify predictive immune biomarkers selective of responders, combination strategies that enhance tumour immunogenicity, and to determine whether these findings extend to other chemoimmunotherapy combinations.
Project Status: Completed
Year Published: 2019
URL for additional information:
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Therapeutics
  • Pharmacology
  • Breast Neoplasms
  • Progression-Free Survival
  • Triple Negative Breast Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
  • Triple negative breast cancer (TNBC)
  • atezolizumab (Tecentriq®)
  • nab-paclitaxel (Abraxane®)
  • first-line therapy
  • anti-PD-L1 antibody
Organisation Name: Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address: Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
Contact Email:
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.